Skip to main content
Moderna10-Q: Product launch

Moderna advancing multiple new vaccine candidates, including norovirus and flu/COVID combo

What happened

The company is committing substantial resources to late-stage clinical development for several new vaccine candidates, signaling a strategic pivot beyond the current COVID market.

Source

SEC EDGARJul 31, 2026

Quarterly report (Form 10-Q)

Moderna 10-Q

Filing excerpt

Our ongoing work on our intismeran autogene, norovirus, and flu plus COVID combination vaccine candidates, our other oncology programs, development of any new COVID vaccines against variants of SARS-CoV-2, late-stage clinical development, investments in digital capabilities and artificial intelligence technologies, and buildout of global commercial, regulatory, sales and marketing infrastructure and manufacturing facilities will require significant cash outflows in future periods...

sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Product launch

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Jul 31, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
1682852
Accession number
0001682852-26-000150
Filing year
2026
Fiscal year
0
Why it matters
Go-to-market support
Signal category
Strategic

Topics and mentions

Technologies

  • vaccine

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Aug 4, 2026
signal_type
sec-10q
signal_subtype
productLaunch

Use this data

Get every 10-Q signal for Moderna and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/2d5ce3d3-bb2b-4302-8c8f-1b7bb8379e4f returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.

{
  "signal_id": "2d5ce3d3-bb2b-4302-8c8f-1b7bb8379e4f",
  "signal_type": "sec-10q",
  "signal_subtype": "productLaunch",
  "detected_at": "2026-08-04T07:07:04.731+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "detail": "The company is committing substantial resources to late-stage clinical development for several new vaccine candidates, signaling a strategic pivot beyond the current COVID market. This pipeline activity will require significant investment in manufacturing, supply chain, and commercial launch readiness, creating opportunities for supporting vendors.",
    "summary": "Moderna advancing multiple new vaccine candidates, including norovirus and flu/COVID combo",
    "excerpts": "Our ongoing work on our intismeran autogene, norovirus, and flu plus COVID combination vaccine candidates, our other oncology programs, development of any new COVID vaccines against variants of SARS-CoV-2, late-stage clinical development, investments in digital capabilities and artificial intelligence technologies, and buildout of global commercial, regulatory, sales and marketing infrastructure and manufacturing facilities will require significant cash outflows in future periods...",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm",
    "filing_date": "2026-07-31",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Go-to-market support",
    "signal_category": "strategic",
    "technologies_mentioned": [
      "vaccine"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.